COVID 19: Management of Decompensated Cirrhosis and Liver Transplant Recipients

Russell Rosenblatt, M.D., M.S. *,†, and Elizabeth C. Verna, M.D., M.S. †,‡

MANAGEMENT OF PATIENTS WITH DECOMPENSATED CIRRHOSIS

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic has resulted in more than 60,000 deaths in the United States as of April 30, 2020.† Although patients with liver disease have been deemed at increased risk for serious illness by the Centers for Disease Control and Prevention,‡ little is known about the natural history of SARS-CoV-2 in liver disease. Patients with advanced liver disease may be at increased risk because of immune dysfunction, frequent hospitalization, high rates of comorbidities (hypertension, diabetes, obesity), and decreased access to antiviral therapies that are potentially hepatotoxic (e.g., remdesivir, interleukin-6 pathway antagonists). In the United States, the prevalence rate of liver disease is 2.3% in patients with SARS-CoV-2,3 and international registries and population-based data suggest a high mortality in cirrhosis.4,5 However, the true prevalence and impact of SARS-CoV-2 on patients with liver disease remains unknown.

Regardless of this prevalence, the SARS-CoV-2 pandemic has caused seismic shifts in the management of patients with advanced liver disease. Lack of access to routine care and decreased yet variable liver transplant (LT) volumes6–8 have caused significant changes in the management of these patients, the impact of which will be significant.

For example, optimal care for patients with cirrhosis includes screening for esophageal varices (EVs) and hepatocellular carcinoma (HCC). Several societies have recommended alterations in current practices based on risk assessment for individual patients.9–11 Although screening

Abbreviations: COVID-2019, coronavirus disease 2019; CSPH, clinically significant portal hypertension; EGD, esophagogastroduodenoscopy; EV, esophageal varix; EVH, esophageal variceal hemorrhage; HCC, hepatocellular carcinoma; LS, liver stiffness; LT, liver transplant; NSBB, nonselective beta blocker; RFA, radiofrequency ablation; Y90, yttrium 90 radioembolization.

From the * Weill Cornell Medicine, 1305 York Avenue, 4th floor, New York, NY; † Center for Liver Disease and Transplantation, 622 West 168th Street, PH 14, New York, NY; and ‡ Columbia University Irving Medical Center, 622 West 168th Street, PH 14, New York, NY.

Potential conflict of interest: R.R. owns stock in Gilead. E.C.V advises Gilead and has received a grant from Salix.

Received May 6, 2020; accepted May 6, 2020.

View this article online at wileyonlinelibrary.com
© 2020 by the American Association for the Study of Liver Diseases

200 | CLINICAL LIVER DISEASE, VOL 15, NO 5, MAY 2020 An Official Learning Resource of AASLD
for varices with esophagogastroduodenoscopy (EGD) among patients with evidence of clinically significant portal hypertension (CSPH) is recommended, liver stiffness <20 to 25 kPa alone or combined with platelets >150,000/mm³ can rule out CSPH with high specificity, reducing the urgency for EGD (Fig. 1). In addition, some have also advocated more liberal use of nonselective beta blockers (NSBBs) in those patients without contraindications who cannot undergo EGD. However, some patients cannot safely delay EGD, including those with acute bleeding or those undergoing serial banding until eradication. The timing and availability of EGD thus depends on several factors, including local SARS-CoV-2 prevalence, patient risk, physician comfort, and the treatment center’s resources.

HCC screening practices have also been significantly impacted. Although screening every 6 months is recommended, the optimal interval based on tumor doubling time is 4 to 8 months. Thus, it is reasonable to marginally prolong HCC screening up to 8 months in selected patients, while being mindful of those with multiple HCC risk factors (Fig. 2). Conversely, in patients with established
or indeterminate HCC who require short-term follow-up or staging, a multidisciplinary discussion is crucial to select individualized treatments and intervals.\textsuperscript{9,10}

**LT EVALUATION AND MANAGEMENT OF TRANSPLANT CANDIDATES**

The LT evaluation process requires extensive noninvasive and invasive testing,\textsuperscript{15,16} and given the appropriate discouragement of in-person visits, telemedicine should be used to expedite LT evaluation.\textsuperscript{9} Data from the Veterans Administration show that telemedicine should be embraced; two recent studies noted that it was associated with a shorter time to transplant listing and ruled out 60\% of futile evaluations.\textsuperscript{17,18}

For patients on the transplant wait list, telehealth visits have become increasingly common, and because of difficulties obtaining laboratory testing regularly, the United Network for Organ Sharing has relaxed its requirement on the frequent updating of Model for End-Stage Liver Disease scores.\textsuperscript{19} For patients with HCC, maintaining treatment of active cancer is crucial. Prioritization of locoregional therapies, such as yttrium 90 radioembolization (Y90),\textsuperscript{20} that reduce time to tumor progression are essential and may be preferable to surgical resection to reduce hospitalization and recovery times.

Finally, whether to proceed with LT for a listed patient must be individualized and based on the patient’s anticipated wait-list survival, local SARS-CoV-2 prevalence, local availability of resources and staff, and ability to test the donor and recipient. Most organ procurement organizations are testing donors, excluding those who test positive for SARS-CoV-2 and, in some cases, even those who are deemed high-risk despite testing negative.\textsuperscript{9,21,22}

**MANAGEMENT OF LT RECIPIENTS**

There is great concern that transplant recipients with chronic immunosuppression could be at high risk for SARS-CoV-2 infection and a severe disease course. Because only a limited number of LT recipients with SARS-CoV-2 have been reported in the literature,\textsuperscript{23,24} the risk for infection and severe outcomes remain unknown. In the largest series of transplant recipients to date, of 13 liver recipients, 31\% had severe disease.\textsuperscript{24} Among the 90 solid organ transplant recipients in this series, 16 (18\%) died, including 24\% of hospitalized patients and 52\% of those who required intensive care. Although time from LT did not significantly predict coronavirus disease 2019 (COVID-19) severity, data from Italy suggest that patients with remote LT on minimal immunosuppression may be paradoxically at high risk for severe disease,\textsuperscript{23} highlighting the important role of the immune response in the severe manifestations of the virus and how little is known about the impact of the amount and type of immunosuppression. Expert panels currently disagree about whether decreased immunosuppression is routinely recommended,\textsuperscript{9,11,22} and there is currently no evidence on which to base recommendations. In addition, the safety and efficacy of antiviral and immunomodulatory strategies in transplant recipients are not established. Thus, treatment in this setting must be individualized according to the patient’s severity of disease, comorbidities, and risk for rejection, all of which may evolve over time.

**UNANSWERED QUESTIONS**

There are many essential unanswered questions regarding the impact of COVID-19 on transplant candidates and recipients. These include basic incidence and prevalence data, which will help guide testing and management of the transplant wait list. This will require accurate and widely available testing for both active SARS-CoV-2 and antibodies indicating prior infection. This must be done quickly to understand whether transplant candidates and recipients are less likely to form antibodies and whether these antibodies confer protection from reinfection. Rapid and accurate testing for the donor and recipient at the time of an offer will be critical to resumption of transplant activities moving forward. We must better understand which aspects of the immune response are helpful or detrimental to tailor immunosuppression management. The risk for SARS-COV-2–related hepatic decompensation or graft rejection is unknown. Finally, to the extent that safety can be maintained, we must advocate that transplant candidates and recipients are studied in clinical trials of investigational and novel antiviral therapeutic strategies to ensure that they are not disadvantaged in this therapeutic arena.

**CORRESPONDENCE**

Elizabeth C. Verna, M.D., M.S., Associate Professor of Medicine, Director of Clinical Research, Transplant Clinical Research Center, Center for Liver Disease and Transplantation, Columbia University Vagelos College of Physicians and Surgeons, 622 West 168th Street, Ph 14-105, New York, NY 10032. E-mail: ev77@cumc.columbia.edu
